Analysis of DAPK1 Signaling Pathway in Stroke

Death-associated protein kinase 1 (DAPK1) is a Ca2+ /calmodulin (CaM)-dependent serine/threonine protein kinase whose phosphorylation contributes to apoptosis. During ischemic stroke, NMDAR overactivation promotes Ca2+ in-flow, activates Ca2+/calmodulin, and stimulates calmodulin phosphatase, which subsequently dephosphorylates and activates DAPK1. DAPK1 is then translocated to the GluN2B subunit of the NMDAR, which exacerbates ischemic injury. Preventing the interaction between GluN2B and DAPK1 attenuates neuronal excitotoxicity in a mouse model of ischemic stroke. Currently, targeting CaM-DAPK1-NR2B is a promising avenue for the treatment of ischemic stroke. Moreover, acting on the DAPK1 pathway not only effectively prevents stroke-induced brain damage, but also does not interfere with the normal physiological function of synaptic transmission.

Fig. 1. Targeting CaM-DAPK1-NR2B is a promising avenue for the treatment of ischemic stroke.Fig. 1. Illustration for DAPK1-NR2B. (Wang et al., 2017)

Our Services

At Ace Therapeutics, our team of high-level biologists is dedicated to deciphering the cellular functions of DAPK1 in stroke, focusing on its biochemical properties, regulation, and especially its target substrates in ischemic injury. We utilize state-of-the-art technologies and approaches to provide comprehensive insights into this critical pathway.

Analysis of Neuronal Cell Death Mediated by DAPK1 Signaling Pathways for Stroke

Through a range of molecular techniques and high-throughput genomics analyses, we aim to help our clients investigate the molecular mechanisms of neuronal cell death mediated by DAPK1 and its downstream signaling pathways involved in multiple pathways during stroke injury.

  • DAPK1-NR2B
  • DAPK1-p53
  • DAPK1-Tau

Stroke Drug Development Services Based on DAPK1 Signaling Pathway

Based on mechanistic studies of the DAPK1 signaling pathway, we can help you develop promising stroke drugs by disrupting DAPK1-related cell death pathways, including but not limited to:

  • Develop DAPK1 inhibitors with sufficient affinity and selective molecular targeting
  • Develop regulatory DAPK1 complex to inhibit DAPK1/NR2B binding
  • Suppress excitotoxicity and inhibit DAPK1 activation by inhibiting CaM activity

Our Advantages

  • Our team consists of experienced experts with in-depth knowledge of stroke pathology and the complexity of the DAPK1 signaling pathway.
  • Our analytical approach combines multiple disciplines, including molecular biology, biochemistry, neurophysiology, and bioinformatics, to capture all aspects of DAPK1 signaling.
  • We offer customized analytical solutions to meet the specific needs of our clients.
  • Detailed and comprehensive reports.

With our expertise, state-of-the-art facilities, and collaborative approach, Ace Therapeutics provides reliable DAPK1 signaling pathway analysis services to identify key targets associated with the DAPK1 pathway in stroke. If you are interested in our services, please do not hesitate to contact us!

  1. Wang, S., et al. (2017). DAPK1 signaling pathways in stroke: from mechanisms to therapies. Molecular neurobiology, 54(6), 4716-4722.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket